Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.
Adès L, Girshova L, Doronin VA, Díez-Campelo M, Valcárcel D, Kambhampati S, Viniou NA, Woszczyk D, De Paz Arias R, Symeonidis A, Anagnostopoulos A, Munhoz EC, Platzbecker U, Santini V, Fram RJ, Yuan Y, Friedlander S, Faller DV, Sekeres MA. Adès L, et al. Among authors: viniou na. Blood Adv. 2022 Sep 13;6(17):5132-5145. doi: 10.1182/bloodadvances.2022007334. Blood Adv. 2022. PMID: 35728048 Free PMC article. Clinical Trial.
High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents.
Terpos E, Katodritou E, Roussou M, Pouli A, Michalis E, Delimpasi S, Parcharidou A, Kartasis Z, Zomas A, Symeonidis A, Viniou NA, Anagnostopoulos N, Economopoulos T, Zervas K, Dimopoulos MA; Greek Myeloma Study Group, Greece. Terpos E, et al. Among authors: viniou na. Eur J Haematol. 2010 Aug;85(2):114-9. doi: 10.1111/j.1600-0609.2010.01466.x. Epub 2010 May 6. Eur J Haematol. 2010. PMID: 20477863
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.
Katodritou E, Terpos E, Symeonidis AS, Pouli A, Kelaidi C, Kyrtsonis MC, Kotsopoulou M, Delimpasi S, Christoforidou A, Giannakoulas N, Viniou NA, Stefanoudaki E, Hadjiaggelidou C, Christoulas D, Verrou E, Gastari V, Papadaki S, Polychronidou G, Papadopoulou A, Giannopoulou E, Kastritis E, Kouraklis A, Konstantinidou P, Anagnostopoulos A, Zervas K, Dimopoulos MA. Katodritou E, et al. Among authors: viniou na. Am J Hematol. 2014 Aug;89(8):803-8. doi: 10.1002/ajh.23745. Epub 2014 May 12. Am J Hematol. 2014. PMID: 24757085 Free article.
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia.
Gambacorti-Passerini CB, Donadoni C, Parmiani A, Pirola A, Redaelli S, Signore G, Piazza V, Malcovati L, Fontana D, Spinelli R, Magistroni V, Gaipa G, Peronaci M, Morotti A, Panuzzo C, Saglio G, Usala E, Kim DW, Rea D, Zervakis K, Viniou N, Symeonidis A, Becker H, Boultwood J, Campiotti L, Carrabba M, Elli E, Bignell GR, Papaemmanuil E, Campbell PJ, Cazzola M, Piazza R. Gambacorti-Passerini CB, et al. Blood. 2015 Jan 15;125(3):499-503. doi: 10.1182/blood-2014-06-579466. Epub 2014 Oct 24. Blood. 2015. PMID: 25343957 Free article.
5-Azacytidine in the Treatment of Intermediate-2 and High-risk Myelodysplastic Syndromes and Acute Myeloid Leukemia. A Five-year Experience with 44 Consecutive Patients.
Diamantopoulos P, Zervakis K, Papadopoulou V, Iliakis T, Kalala F, Giannakopoulou N, Rougala N, Galanopoulos A, Bakarakos P, Variami E, Dimitrakopoulou A, Viniou NA. Diamantopoulos P, et al. Among authors: viniou na. Anticancer Res. 2015 Sep;35(9):5141-7. Anticancer Res. 2015. PMID: 26254419
The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group.
Papageorgiou SG, Vasilatou D, Kontos CK, Kotsianidis I, Symeonidis A, Galanopoulos AG, Hatzimichael E, Megalakaki A, Poulakidas E, Diamantopoulos P, Vassilakopoulos TP, Zikos P, Papadaki H, Mparmparousi D, Bouronikou E, Panayiotidis P, Viniou NA, Pappa V. Papageorgiou SG, et al. Among authors: viniou na. Am J Hematol. 2018 Jul;93(7):895-901. doi: 10.1002/ajh.25111. Epub 2018 May 16. Am J Hematol. 2018. PMID: 29659040 Free article.
The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group.
Papageorgiou SG, Kontos CK, Kotsianidis I, Vasilatou D, Symeonidis A, Galanopoulos A, Bouchla A, Hatzimichael E, Repousis P, Zikos P, Viniou NA, Poulakidas E, Vassilakopoulos TP, Diamantopoulos P, Diamantopoulos MA, Mparmparousi D, Bouronikou E, Papadaki H, Panayiotidis P, Pappa V. Papageorgiou SG, et al. Among authors: viniou na. Hematol Oncol. 2018 Oct;36(4):693-700. doi: 10.1002/hon.2551. Epub 2018 Sep 7. Hematol Oncol. 2018. PMID: 30129144
Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system.
Diamantopoulos PT, Kotsianidis I, Symeonidis A, Pappa V, Galanopoulos A, Gogos D, Karakatsanis S, Papadaki H, Palla A, Hatzimichael E, Dimou M, Papageorgiou S, Delimpasis S, Papaioannou M, Papoutselis M, Kourakli A, Tsokanas D, Anagnostopoulos A, Kontos CK, Panayiotidis P, Viniou NA; Hellenic MDS study group. Diamantopoulos PT, et al. Among authors: viniou na. Leuk Lymphoma. 2019 Jul;60(7):1721-1730. doi: 10.1080/10428194.2018.1540783. Epub 2018 Nov 14. Leuk Lymphoma. 2019. PMID: 30424699
Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome.
Diamantopoulos PT, Kontandreopoulou CN, Symeonidis A, Kotsianidis I, Pappa V, Galanopoulos A, Vassilakopoulos T, Dimou M, Solomou E, Kyrtsonis MC, Siakantaris M, Angelopoulou M, Kourakli A, Papageorgiou S, Christopoulou G, Roumelioti M, Panayiotidis P, Viniou NA; Hellenic MDS Study Group. Diamantopoulos PT, et al. Among authors: viniou na. Ann Hematol. 2019 Jun;98(6):1383-1392. doi: 10.1007/s00277-019-03650-w. Epub 2019 Mar 15. Ann Hematol. 2019. PMID: 30877373
The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registry.
Diamantopoulos P, Koumbi D, Kotsianidis I, Pappa V, Symeonidis A, Galanopoulos A, Zikos P, Papadaki HA, Panayiotidis P, Dimou M, Hatzimichael E, Vassilopoulos G, Delimpasis S, Mparmparousi D, Papageorgiou S, Variami E, Kyrtsonis MC, Megalakaki A, Kotsopoulou M, Repousis P, Adamopoulos I, Kontopidou F, Christoulas D, Kourakli A, Tsokanas D, Konstantinos Papoutselis M, Kyriakakis G, Viniou NA; Hellenic MDS study group. Diamantopoulos P, et al. Among authors: viniou na. Cancer Med. 2019 May;8(5):2056-2063. doi: 10.1002/cam4.2090. Epub 2019 Mar 21. Cancer Med. 2019. PMID: 30897290 Free PMC article.
117 results